Martin Investment Management LLC lifted its stake in Johnson & Johnson (NYSE:JNJ) by 0.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 64,142 shares of the company’s stock after purchasing an additional 289 shares during the quarter. Martin Investment Management LLC’s holdings in Johnson & Johnson were worth $8,299,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds also recently bought and sold shares of the company. Virtus ETF Advisers LLC purchased a new position in Johnson & Johnson in the 2nd quarter worth about $25,000. Krane Funds Advisors LLC purchased a new position in Johnson & Johnson in the 2nd quarter worth about $26,000. Financial Advantage Inc. purchased a new position in Johnson & Johnson in the 3rd quarter worth about $28,000. Crewe Advisors LLC raised its position in Johnson & Johnson by 725.9% in the 2nd quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock worth $31,000 after buying an additional 196 shares during the last quarter. Finally, Eii Capital Management Inc. purchased a new position in Johnson & Johnson in the 3rd quarter worth about $39,000. 72.22% of the stock is owned by hedge funds and other institutional investors.
A number of equities analysts have weighed in on the company. Credit Suisse Group boosted their target price on Johnson & Johnson from $158.00 to $163.00 in a research report on Thursday, October 24th. Goldman Sachs Group set a $169.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Raymond James decreased their target price on Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating for the company in a research report on Monday, October 14th. Wells Fargo & Co decreased their target price on Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating for the company in a research report on Wednesday, October 16th. Finally, Atlantic Securities raised shares of Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research report on Wednesday, October 16th. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Johnson & Johnson currently has an average rating of “Buy” and a consensus price target of $151.64.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.00 by $0.12. The business had revenue of $20.73 billion during the quarter, compared to analyst estimates of $20.14 billion. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.81%. The company’s revenue was up 1.9% on a year-over-year basis. During the same period in the prior year, the business posted $2.05 earnings per share. Equities analysts anticipate that Johnson & Johnson will post 8.65 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a $0.95 dividend. The ex-dividend date of this dividend is Monday, November 25th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.90%. Johnson & Johnson’s payout ratio is currently 46.45%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: Risk Tolerance
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.